Current News

Print version | PDF version | Send article | RSS-Feed

Lundbeck further strengthens pipeline by moving Lu AA34893 into clinical phase II

20 Feb 2008 - H. Lundbeck A/S has decided to investigate Lu AA34893 for the treatment of bipolar disorder. The decision is based on positive pre-clinical results as well as positive conclusion of the phase I trials in healthy individuals.
 
The first patients in a 600-patient Phase II study have now been enrolled. The study will investigate the effects of Lu AA34893 on the depressive episodes in bipolar disorder and its potential to prevent occurrence of mania.
 
Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of mood disorder. The mechanism of action for Lu AA34893 incorporates a number of monoaminergic systems and includes allosteric effects. Thus, the compound has a potential profile that is superior to other treatments currently used in bipolar disorders.
 
"Lu AA34893 belongs to a new generation of psychotropics with a strong potential to show long-term effective mood stabilisation and thereby prevention of long-term disability in patients suffering from bipolar disorder. This study marks the first entry into bipolar disorder for Lundbeck and if successful, Lu AA34893 will provide a completely new approach to treat the needs of patients with bipolar disorder", said Senior Vice President Anders Gersel Pedersen, head of Development at Lundbeck. "We are very pleased with the fact that Lundbeck's development pipeline never has been as broad based as is the case today."
 
The in vitro pharmacological profile of the compound shows that the compound combines potent effects on several serotonin receptors and serotonin transporter proteins.